Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alberto Briganti

Showing results (81-90 of 1,750) with videos related to

Pageof 175
Sort By:
European Urology|April 2, 2014
Metabolic syndrome as a marker for prostate cancer: still a work in progressAndrea Gallina, Alessandro Nini, Francesco Montorsi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 2, 2014
Will focal therapy remain only an attractive illusion for the primary treatment of prostate cancer?Gianluca Giannarini, Giorgio Gandaglia, Francesco Montorsi, et al.
British Journal of Cancer|October 26, 2016
Comment on 'Validation of a contemporary prostate cancer grading system using prostate cancer death as outcome'Paolo Dell'Oglio, Armando Stabile, Giorgio Gandaglia, et al.
The Journal of Urology|September 6, 2023
Early Detection of Prostate Cancer: AUA/SUO Guideline. LetterFrancesco Montorsi, Giorgio Gandaglia, Andrea Salonia, et al.
European Urology|February 4, 2018
Reply to Mustafa Z. Temiz and Huseyin Besiroglu's Letter to the Editor re: Giorgio Gandaglia, Stephen A. Boorjian, William P. Parker, et al. Impact of Postoperative Radiotherapy in Men with Persistently Elevated Prostate-specific Antigen After Radical Prostatectomy for Prostate Cancer: A Long-term Survival Analysis. Eur Urol 2017;72:910-7Giorgio Gandaglia, Nicola Fossati, Francesco Montorsi, et al.
European Urology|January 26, 2020
Re: Felix Preisser, Felix K.H. Chun, Raisa S. Pompe, et al. Persistent Prostate-Specific Antigen After Radical Prostatectomy and Its Impact on Oncologic Outcomes. Eur Urol 2019;76:106-14Francesco Montorsi, Nicola Fossati, Giorgio Gandaglia, et al.
The Journal of Urology|April 10, 2023
Repeat Transurethral Resection of Muscle-invasive Bladder Cancer Prior to Radical Cystectomy Is Prognostic but Not Therapeutic. LetterMarco Moschini, Andrea Necchi, Alberto Briganti, et al.
The Journal of Urology|February 8, 2024
Letter: Treatment of Low-Grade Intermediate-Risk Nonmuscle-Invasive Bladder Cancer with UGN-102 ± Transurethral Resection of Bladder Tumor Compared to Transurethral Resection of Bladder Tumor Monotherapy: A Randomized, Controlled, Phase 3 Trial (ATLAS)Francesco Montorsi, Marco Moschini, Giorgio Gandaglia, et al.
BJU International|October 3, 2025
Re: 'Real-world use of androgen-deprivation therapy intensification for metastatic hormone-sensitive prostate cancer: a systematic review'Simone Scuderi, Giorgio Gandaglia, Alberto Briganti, et al.
European Urology|December 4, 2015
Excellent Erectile Function Recovery after Focal Therapy: Is This Enough?Giorgio Gandaglia, Alberto Briganti, Andrea Salonia, et al.
Pageof 175

Showing results (81-90 of 1,750) with videos related to

Sort By:
Pageof 175
European Urology|April 2, 2014
Metabolic syndrome as a marker for prostate cancer: still a work in progressAndrea Gallina, Alessandro Nini, Francesco Montorsi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 2, 2014
Will focal therapy remain only an attractive illusion for the primary treatment of prostate cancer?Gianluca Giannarini, Giorgio Gandaglia, Francesco Montorsi, et al.
British Journal of Cancer|October 26, 2016
Comment on 'Validation of a contemporary prostate cancer grading system using prostate cancer death as outcome'Paolo Dell'Oglio, Armando Stabile, Giorgio Gandaglia, et al.
The Journal of Urology|September 6, 2023
Early Detection of Prostate Cancer: AUA/SUO Guideline. LetterFrancesco Montorsi, Giorgio Gandaglia, Andrea Salonia, et al.
European Urology|February 4, 2018
Reply to Mustafa Z. Temiz and Huseyin Besiroglu's Letter to the Editor re: Giorgio Gandaglia, Stephen A. Boorjian, William P. Parker, et al. Impact of Postoperative Radiotherapy in Men with Persistently Elevated Prostate-specific Antigen After Radical Prostatectomy for Prostate Cancer: A Long-term Survival Analysis. Eur Urol 2017;72:910-7Giorgio Gandaglia, Nicola Fossati, Francesco Montorsi, et al.
European Urology|January 26, 2020
Re: Felix Preisser, Felix K.H. Chun, Raisa S. Pompe, et al. Persistent Prostate-Specific Antigen After Radical Prostatectomy and Its Impact on Oncologic Outcomes. Eur Urol 2019;76:106-14Francesco Montorsi, Nicola Fossati, Giorgio Gandaglia, et al.
The Journal of Urology|April 10, 2023
Repeat Transurethral Resection of Muscle-invasive Bladder Cancer Prior to Radical Cystectomy Is Prognostic but Not Therapeutic. LetterMarco Moschini, Andrea Necchi, Alberto Briganti, et al.
The Journal of Urology|February 8, 2024
Letter: Treatment of Low-Grade Intermediate-Risk Nonmuscle-Invasive Bladder Cancer with UGN-102 ± Transurethral Resection of Bladder Tumor Compared to Transurethral Resection of Bladder Tumor Monotherapy: A Randomized, Controlled, Phase 3 Trial (ATLAS)Francesco Montorsi, Marco Moschini, Giorgio Gandaglia, et al.
BJU International|October 3, 2025
Re: 'Real-world use of androgen-deprivation therapy intensification for metastatic hormone-sensitive prostate cancer: a systematic review'Simone Scuderi, Giorgio Gandaglia, Alberto Briganti, et al.
European Urology|December 4, 2015
Excellent Erectile Function Recovery after Focal Therapy: Is This Enough?Giorgio Gandaglia, Alberto Briganti, Andrea Salonia, et al.
Pageof 175